Advanced search
1 file | 349.25 KB Add to list

The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon : a Belgian experience

(2017) JOURNAL OF VIRAL HEPATITIS. 24(11). p.976-981
Author
Organization
Abstract
Recently, concerns were raised of high rates of HCC recurrence in patients treated with direct-acting antivirals (DAA) for hepatitis C infection. We investigated the HCC occurrence and recurrence rates within 6 months after treatment with DAA with or without pegylated interferon (PEG-IFN) in real life. This is a retrospective, multicenter cohort trial, executed in 15 hospitals distributed across Belgium. Populations were matched based on fibrosis score (Metavir F3-F4). Patients with a Child-Pugh score >= B were excluded. In total, 567 patients were included, of whom 77 were treated with PEG-IFN+DAA between 2008 and 2013 and 490 with DAA without PEG-IFN between 2013 and 2015. Patients treated with PEG-IFN+DAA (53 +/- 9y) were younger than patients treated with DAA without PEG-IFN (59 +/- 12y) (P=. 001). 47% of patients treated with PEG-IFN+DAA were in the F4 stage vs 67% of patients treated with DAA without PEG-IFN (P=. 001). Screening was inadequate in 20% of both patient groups (P=. 664). The early occurrence rate of HCC was 1.7% and 1.1% in patients treated with DAA with and without PEG-IFN, respectively (P=. 540). The early recurrence rate was 0% in patients treated with PEG-IFN+DAA and 15.0% in patients treated with DAA without PEG-IFN (P=. 857). There is no difference in early occurrence of new HCC between patients treated with DAA with and without PEG-IFN. We did observe a high early recurrence rate of HCC in patients treated with DAA without PEG-IFN. However, these patients were at baseline more at risk for HCC. Finally, in 20%, screening for HCC was inadequate.
Keywords
SUSTAINED VIROLOGICAL RESPONSE, VIRUS-RELATED CIRRHOSIS, CHRONIC HCV, INFECTION, GENOTYPE 1, COMPENSATED CIRRHOSIS, PORTAL-HYPERTENSION, PROSPECTIVE COHORT, RIBAVIRIN THERAPY, PLUS SOFOSBUVIR, VELPATASVIR, direct-acting antiviral therapy, hepatitis C, hepatocellular carcinoma, pegylated interferon

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 349.25 KB

Citation

Please use this url to cite or link to this publication:

MLA
Bielen, R et al. “The Risk of Early Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C-infected Patients Treated with Direct-acting Antivirals with and Without Pegylated Interferon : a Belgian Experience.” JOURNAL OF VIRAL HEPATITIS 24.11 (2017): 976–981. Print.
APA
Bielen, R, Moreno, C., Van Vlierberghe, H., Bourgeois, S., Mulkay, J.-P., Vanwolleghem, T., Verlinden, W., et al. (2017). The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon : a Belgian experience. JOURNAL OF VIRAL HEPATITIS, 24(11), 976–981.
Chicago author-date
Bielen, R, C Moreno, Hans Van Vlierberghe, S Bourgeois, J-P Mulkay, T Vanwolleghem, W Verlinden, et al. 2017. “The Risk of Early Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C-infected Patients Treated with Direct-acting Antivirals with and Without Pegylated Interferon : a Belgian Experience.” Journal of Viral Hepatitis 24 (11): 976–981.
Chicago author-date (all authors)
Bielen, R, C Moreno, Hans Van Vlierberghe, S Bourgeois, J-P Mulkay, T Vanwolleghem, W Verlinden, C Brixco, J Decaestecker, C de Galocsy, F Janssens, L Van Overbeke, Christophe Van Steenkiste, F D’Heygere, M Cool, K Wuyckens, F Nevens, and G Robaeys. 2017. “The Risk of Early Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C-infected Patients Treated with Direct-acting Antivirals with and Without Pegylated Interferon : a Belgian Experience.” Journal of Viral Hepatitis 24 (11): 976–981.
Vancouver
1.
Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay J-P, Vanwolleghem T, et al. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon : a Belgian experience. JOURNAL OF VIRAL HEPATITIS. 2017;24(11):976–81.
IEEE
[1]
R. Bielen et al., “The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon : a Belgian experience,” JOURNAL OF VIRAL HEPATITIS, vol. 24, no. 11, pp. 976–981, 2017.
@article{8535589,
  abstract     = {Recently, concerns were raised of high rates of HCC recurrence in patients treated with direct-acting antivirals (DAA) for hepatitis C infection. We investigated the HCC occurrence and recurrence rates within 6 months after treatment with DAA with or without pegylated interferon (PEG-IFN) in real life. This is a retrospective, multicenter cohort trial, executed in 15 hospitals distributed across Belgium. Populations were matched based on fibrosis score (Metavir F3-F4). Patients with a Child-Pugh score >= B were excluded. In total, 567 patients were included, of whom 77 were treated with PEG-IFN+DAA between 2008 and 2013 and 490 with DAA without PEG-IFN between 2013 and 2015. Patients treated with PEG-IFN+DAA (53 +/- 9y) were younger than patients treated with DAA without PEG-IFN (59 +/- 12y) (P=. 001). 47% of patients treated with PEG-IFN+DAA were in the F4 stage vs 67% of patients treated with DAA without PEG-IFN (P=. 001). Screening was inadequate in 20% of both patient groups (P=. 664). The early occurrence rate of HCC was 1.7% and 1.1% in patients treated with DAA with and without PEG-IFN, respectively (P=. 540). The early recurrence rate was 0% in patients treated with PEG-IFN+DAA and 15.0% in patients treated with DAA without PEG-IFN (P=. 857). There is no difference in early occurrence of new HCC between patients treated with DAA with and without PEG-IFN. We did observe a high early recurrence rate of HCC in patients treated with DAA without PEG-IFN. However, these patients were at baseline more at risk for HCC. Finally, in 20%, screening for HCC was inadequate.},
  author       = {Bielen, R and Moreno, C and Van Vlierberghe, Hans and Bourgeois, S and Mulkay, J-P and Vanwolleghem, T and Verlinden, W and Brixco, C and Decaestecker, J and de Galocsy, C and Janssens, F and Van Overbeke, L and Van Steenkiste, Christophe and D'Heygere, F and Cool, M and Wuyckens, K and Nevens, F and Robaeys, G},
  issn         = {1352-0504},
  journal      = {JOURNAL OF VIRAL HEPATITIS},
  keywords     = {SUSTAINED VIROLOGICAL RESPONSE,VIRUS-RELATED CIRRHOSIS,CHRONIC HCV,INFECTION,GENOTYPE 1,COMPENSATED CIRRHOSIS,PORTAL-HYPERTENSION,PROSPECTIVE COHORT,RIBAVIRIN THERAPY,PLUS SOFOSBUVIR,VELPATASVIR,direct-acting antiviral therapy,hepatitis C,hepatocellular carcinoma,pegylated interferon},
  language     = {eng},
  number       = {11},
  pages        = {976--981},
  title        = {The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon : a Belgian experience},
  url          = {http://dx.doi.org/10.1111/jvh.12726},
  volume       = {24},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: